Hoth Therapeutics (NASDAQ:HOTH) Issues Earnings Results, Misses Estimates By $0.06 EPS

Hoth Therapeutics (NASDAQ:HOTH) issued its quarterly earnings data on Friday. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.06), FiscalAI reports.

Hoth Therapeutics Stock Down 4.0%

NASDAQ HOTH opened at $0.81 on Friday. Hoth Therapeutics has a twelve month low of $0.66 and a twelve month high of $2.12. The business has a 50-day moving average price of $0.97 and a 200-day moving average price of $1.20. The firm has a market cap of $12.49 million, a price-to-earnings ratio of -0.76 and a beta of 0.50.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC grew its holdings in Hoth Therapeutics by 8.0% during the 2nd quarter. Geode Capital Management LLC now owns 122,575 shares of the company’s stock valued at $143,000 after buying an additional 9,071 shares in the last quarter. Virtu Financial LLC purchased a new position in shares of Hoth Therapeutics in the third quarter worth $184,000. Citadel Advisors LLC bought a new position in shares of Hoth Therapeutics during the third quarter worth $232,000. Lido Advisors LLC bought a new position in shares of Hoth Therapeutics during the third quarter worth $32,000. Finally, Kestra Private Wealth Services LLC purchased a new position in Hoth Therapeutics during the third quarter valued at $51,000. 7.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

HOTH has been the subject of a number of research reports. Wall Street Zen upgraded shares of Hoth Therapeutics to a “sell” rating in a research note on Saturday, March 7th. D. Boral Capital reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Hoth Therapeutics in a report on Wednesday. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Hoth Therapeutics in a research report on Monday, December 22nd. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $5.00.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the acquisition, licensing and development of novel therapies for dermatological, central nervous system and other debilitating conditions. The company’s strategy emphasizes in-licensing late preclinical or early clinical assets with promising pharmacological profiles and leveraging formulation science to optimize delivery. Core to its approach is the design of topical and localized administration platforms intended to enhance drug penetration, sustain release and reduce systemic exposure.

Hoth’s development pipeline encompasses multiple candidate programs addressing high-unmet-need areas such as atopic dermatitis, epidermolysis bullosa and oral mucositis.